美国食品和药物管理局批准Bristol Myers实验性阿尔茨海默病药物BMS-986446的快速治疗. FDA grants fast-track status to Bristol Myers' experimental Alzheimer’s drug BMS-986446 targeting tau protein.

Bristol Myers Squibb已经获得FDA快速指定BMS-986446BMS-986446,这是针对早期阿尔茨海默氏病的实验性抗体,该抗体针对有微管结合作用的Tau蛋白区域。 Bristol Myers Squibb has received FDA fast-track designation for BMS-986446, an experimental antibody targeting the microtubule-binding region of tau protein, for early Alzheimer’s disease. 在第二阶段试验中,该药物旨在通过阻止非正常的Tau传播和加强其从大脑的去除来减缓疾病的蔓延。 The drug, in Phase 2 trials, aims to slow disease progression by stopping abnormal tau spread and enhancing its removal from the brain. 美国食品和药物管理局的快速发展状态加速了治疗严重疾病的开发和审查, The FDA’s fast-track status accelerates development and review for therapies addressing serious conditions with significant unmet needs. 不仅有症状, 更能改变阿尔茨海默氏病的病情发展。 The designation highlights the drug’s potential to modify Alzheimer’s progression, not just symptoms.